ALNY News and Press, Alnylam Pharmaceuticals Inc. From 07/24/23

– Partnership Combines Alnylam’s Leadership in RNAi Therapeutics with Roche’s Proven Track Record of Successfully Developing and Launching Innovative Medicines Worldwide – – Zilebesiran Represents a Potentially Transformative Approach to Reducing CV ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2023 on Thursday, August 3, 2023, before the U.S. financial markets open. Management will provide an update on th...

— Dose-Dependent Reductions in Serum Angiotensinogen and 24-hour Ambulatory Blood Pressure Were Sustained for Six Months After Single Doses of Zilebesiran — — Acceptable Safety Profile Supporting Further Development — Alnylam Pharmaceuticals, Inc....

2023-07-17 18:42:44 ET Summary Primary endpoint met in BridgeBio Pharma, Inc.'s phase 3 ATTRibute-CM study, which used acoramidis for the treatment of patients with transthyretin amyloid cardiomyopathy; NDA filing expected before end of 2023. Results from the phase 3 ATTRibute-CM ...

2023-07-17 18:29:00 ET The fight against Alzheimer's disease seems to be advancing, and one biotech developing a treatment for the degenerative brain disorder benefited from this on Monday. This was Alnylam Pharmaceuticals (NASDAQ: ALNY) , which saw its share price rise by nearl...

– First Clinical Study of a Central Nervous System-Administered RNAi Therapeutic Showed Rapid and Robust Target Engagement with Sustained Effect Over 6 Months with a Single Dose – – ALN-APP Continues to Demonstrate an Encouraging Clinical Safety and Tolerability Profi...

2023-07-07 05:07:59 ET Summary Regeneron's stock price has suffered a setback due to concerns over the future of Eylea, its flagship drug, as competition and potential drug pricing regulations loom. The company's immunology collaboration with Sanofi continues to show promise, part...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has set a date of September 13, 2023 for the meeting of the Cardiovascular and Renal Drugs Advisory Committee to review the supplemental New Drug...

2023-06-15 11:57:12 ET Reata Pharmaceuticals ( NASDAQ: RETA ) shed ~13% in the morning hours Thursday after the company's chief financial officer and chief operating officer Manmeet Soni sold millions of dollars worth of its shares early this week. According to a regula...

2023-06-13 17:55:37 ET Summary Regeneron Pharmaceuticals, Inc. has potential to receive FDA approval of higher dosing of 8 mg of EYLEA, which has been set with an FDA target action date of June 27, 2023. The additional indication in preterm infants with retinopathy of prematurity ...